Fate Therapeutics Reports Q2 2026 Results: First Patient Dosed in Pivotal Lupus Nephritis Trial, Cash Runway into 2028
FATE has more than doubled off its 52-week low of $0.923 on light trading volume (0.3× avg).
Summary
Fate Therapeutics reported Q2 2026 results with first patient dosed in its pivotal lupus nephritis trial, FDA clearance for FT839, and cash runway extended into 2028.
Key Events · Earnings and Guidance · FATE
-
First Patient Dosed in Pivotal Trial
First patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis. Patient treated as outpatient with same-day discharge.
-
FT839 IND Cleared
FDA cleared IND for FT839, a dual CD19/CD38 targeting off-the-shelf CAR T-cell therapy, advancing into a Phase 1/2 basket trial in autoimmune disease.
-
Positive SSc Data
Preliminary data in systemic sclerosis showed rCRISS25 or greater responses and improvement in mRSS in all four treated patients, with no CRS, ICANS, GvHD, or hypogammaglobulinemia.
-
Cash Runway Extended
Cash, cash equivalents, and investments of $153.8 million as of June 30, 2026, with quarterly decrease of $21 million. Runway expected into 2028.
Analysis · FATE · Life Sciences
Fate Therapeutics delivered a quarter of meaningful clinical progress alongside solid financials. The first patient dosed in the RECLAIM-LN Phase 2 potentially registrational trial for FT819 in lupus nephritis is a major de-risking event for the company's lead program. The FDA clearance of FT839's IND (previously announced in July) and positive early data in systemic sclerosis further validate the off-the-shelf CAR T-cell platform. Financially, the company reduced operating expenses by 14.3% year-over-year, extending cash runway into 2028 with $153.8 million in cash and investments. The appointment of Laura Hamill to the board adds commercial expertise as the company prepares for potential commercialization. While the net loss of $30.2 million is in line with expectations, the combination of clinical milestones and extended runway makes this a notable update for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FATE was trading at $2.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $317M. The 52-week trading range was $0.92 to $3.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.